The decision of when and how to proceed on defining key parameters of the 340B drug discount program now rests with the Trump Administration.
HRSA formally withdrew the final version of the 340B “mega-guidance” from review at the Office of Management & Budget on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?